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OBJECTIVES The aim of this study was to examine the echocardiographic features and associations of
mitral valve prolapse (MVP) diagnosed by current two-dimensional echocardiographic
criteria in an unselected outpatient sample.
BACKGROUND Previous studies of patients with MVP have emphasized the frequent occurrence of
echocardiographic abnormalities such as significant mitral regurgitation (MR) and left atrial
(LA) enlargement that are associated with clinical complications. These studies, however,
have been limited by the use of hospital-based or referral series.
METHODS We quantitatively studied all 150 subjects with possible MVP by echocardiography and 150
age- and gender-matched subjects without MVP from the 3,491 subjects in the Framingham
Heart Study. Based on leaflet morphology, subjects were classified as having classic (n  46),
nonclassic (n  37), or no MVP.
RESULTS Leaflet length, MR degree, and LA and left ventricular size were significantly but mildly
increased in MVP (p  0.0001 to 0.004), with mean values typically within normal range.
Average MR jet area was 15.1  1.4% (mild) in classic MVP and 8.9  1.5% (trace) in
nonclassic MVP; MR was severe in only 3 of 46 (6.5%) subjects with classic MVP, and LA
volume was increased in only 8.7% of those with classic MVP and 2.7% of those with
nonclassic MVP.
CONCLUSIONS Although the echocardiographic characteristics of subjects with MVP in the Framingham
Heart Study differ from those without MVP, they display a far more benign profile of
associated valvular, atrial, and ventricular abnormalities than previously reported in hospital-
or referral-based series. Therefore, these findings may influence the perception of and
approach to the outpatient with MVP. (J Am Coll Cardiol 2002;40:1298–304) © 2002 by
the American College of Cardiology Foundation
Mitral valve prolapse (MVP) has been described as the most
common cardiac valvular abnormality in industrialized
countries (1) and the leading cause of mitral valve surgery
for isolated mitral regurgitation (MR) (2). Previous studies
have emphasized the frequent occurrence of echocardio-
graphic abnormalities in patients with MVP, including
thickened and elongated leaflets with important MR and
left heart chamber enlargement. These abnormalities, in
turn, have been associated with clinical complications in as
many as 10% to 46% of patients in those series, including
congestive heart failure, mitral valve surgery, bacterial en-
docarditis, arrhythmias, and sudden death (3–19). Those
studies, however, have been limited by the use of hospital-
based or highly selected referral samples more likely to have
echocardiographic and clinical abnormalities, similar to the
experience with referral populations in hypertrophic cardio-
myopathy (20,21). This perception of disease severity has
affected individuals receiving the diagnosis, increasing per-
sonal and professional anxiety concerning the risk of com-
plications and the need for prophylaxis.
A contrasting impression is that MVP is a common
disorder (22–31), often affecting individuals who otherwise
appear healthy (32,33). This impression, however, may
relate to prior use of M-mode or two-dimensional (2-D)
echocardiographic views nonspecific for the diagnosis of
MVP (23,31,34–38). Recent understanding of the three-
dimensional nonplanar shape of the mitral annulus (39–45)
has allowed us to refine the 2-D echocardiographic criteria
for MVP to minimize false positive diagnoses (46,47). To
date, however, no study has applied these criteria to a
community-based sample to characterize the echocardio-
graphic manifestations of MVP. Therefore, this study
examined the echocardiographic features of MVP as diag-
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nosed by current 2-D echocardiographic criteria in an
unselected outpatient sample, as provided by the Framing-
ham Heart Study.
METHODS
Study sample. The Framingham Heart Study was estab-
lished in 1948 as a prospective epidemiologic cohort inves-
tigation. Offspring of the original cohort and the spouses of
offspring were entered into a prospective study in 1971
(48,49). Subjects who participated in the fifth offspring
examination (1991 to 1995) were the focus of this study.
The examination protocol was approved by the Boston
Medical Center Institutional Review Board, and all subjects
gave informed consent.
The study sample consisted of all 3,491 subjects at the
fifth offspring examination (1,845 women, 1,646 men) with
technically adequate 2-D echocardiograms (245 subjects
were eliminated because of technically inadequate echocar-
diograms for evaluating the mitral valve). Of this cohort,
five subjects had a history of mitral valve repair or replace-
ment, four of whom had documented pathologies other
than MVP (mitral stenosis, ischemic MR). Only one subject
had mitral valve surgery (repair) for MVP. These subjects
were excluded from echocardiographic analysis because the
measured variables could have been altered by the surgical
intervention. To ensure complete ascertainment of MVP,
we examined the echocardiograms of all subjects who were
previously identified as having possible leaflet displacement
suggesting prolapse in any 2-D view or by M-mode at any
study exam (offspring exams 2,4,5). This broad-net ap-
proach identified 518 subjects. First, we assessed the fifth-
examination echocardiograms of these 518 subjects to iden-
tify those in whom approach of the leaflets toward the
annulus or qualitative superior systolic mitral leaflet dis-
placement warranted quantitative evaluation to determine
whether prolapse was actually present. Cases identified in
this way (n  150) were paired with age- and gender-
matched control subjects drawn from the fifth offspring
exam who were initially coded as having no evidence of
MVP. Echocardiograms of cases and control subjects were
examined blinded to MVP status and clinical history.
Echocardiographic methods. All subjects underwent stan-
dard 2-D echocardiograms with a commercially available
system (Hewlett-Packard Sonos 1000, Andover, Massachu-
setts) using a 2.5-MHz transducer. Images were recorded
on videotape, including complete parasternal, apical, and
subcostal views, and color Doppler to assess valvular regur-
gitation. All measurements were performed using a Sony
Off-Line Cardiac Analysis System (Sum 1010, Sony, Park
Ridge, New Jersey).
Using current 2-D echocardiographic criteria based on
the three-dimensional shape of the annulus and clinical
correlations (14,39–47), the diagnosis of MVP was made
by measurement of maximal mitral leaflet superior systolic
displacement relative to the line connecting the annular
hinge points. Displacement of the anterior and posterior
mitral leaflets was measured in the parasternal and apical
long-axis views, which were scanned by tilting the trans-
ducer to visualize the medial, central, and lateral scallops of
the posterior leaflet (14,39,40,46,47). Because the lateral
scallop of the posterior leaflet is most difficult to evaluate
from these views, and in order to ensure its complete
assessment, its displacement was also measured in the apical
four-chamber view (46,50); however, such displacement
could always be confirmed in the long-axis scans. Mitral
leaflet thickness in diastasis was measured as the leading to
trailing edge of the thickest area of the midportion of the
leaflet, excluding focal areas of thickness and chordae
(4,14,46,51,52). Each leaflet was measured, and maximal
thickness was used for categorization. On the basis of prior
clinical and prognostic studies, subjects were classified as
having classic MVP (displacement 2 mm, thickness 5
mm) or nonclassic MVP (displacement 2 mm, thickness
5 mm) (4,5,14,46,47). Borderline degrees of displacement
(2 mm) have been shown to lack association with in-
creased leaflet thickness, MR, left atrial (LA) enlargement,
valve-related complications, or progression over 10 years
and were not included as prolapse (46).
Maximal mitral annular diameter was measured at end-
systole as the length of the line connecting the midportion
of the leaflet hinge points in the parasternal long-axis view
(51). The lengths of the anterior and posterior mitral leaflets
were traced in diastasis in the parasternal long-axis view
from their hinge points to the free edges along the middle
of the leaflets, excluding the chordae (51). The degree of
MR was assessed as maximal regurgitant jet area/LA area
ratio in the parasternal and apical long-axis and apical
four-chamber views (53). Trace, mild, moderate, and severe
MR were classified on the basis of jet area/LA area ratios of
0% to 10%, 10% to 20%, 20% to 40%, and 40%
(53).
Three maximal end-systolic LA dimensions were mea-
sured: the anteroposterior diameter obtained in the paraster-
nal long-axis view at the aortic leaflet insertion points; and
the mediolateral and inferosuperior diameters obtained in
the apical four-chamber view and passing through the
midpoint of the visualized atrial area (46). Left atrial volume
was calculated as the product of these dimensions  /6 to
give the volume of an ellipsoid (46). Left ventricular internal
diameter in end-systole (LVIDs) and left ventricular inter-
nal diameter in end-diastole (LVIDd) were measured in the
Abbreviations and Acronyms
2-D  two-dimensional
LA  left atrial/atrium
LV  left ventricle/ventricular
LVIDd  left ventricular internal diameter in end-
diastole
LVIDs  left ventricular internal diameter in end-systole
MR  mitral regurgitation
MVP  mitral valve prolapse
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parasternal long-axis view below the mitral leaflet tips as
recommended by the American Society of Echocardiogra-
phy (54). Left ventricular ejection fraction was calculated as
follows: ([LVIDd2  LVIDs2]/LVIDd2)  100  10% for
a normal apex, as all subjects had a normal apex (55).
All measurements, except jet and LA area, were made in
the same view on two separate cardiac cycles that provided
unambiguous identification of the structures, and the two
values were averaged. No measurements were made on
premature or post-premature atrial or ventricular beats. The
intraobserver (L. A. F.) and interobserver (L. A. F. and
R. A. L.) correlations for mitral leaflet displacement, leaflet
thickness, and degree of MR in 20 subjects exceeded 0.97.
Associated echocardiographic features. Other echocar-
diographic features associated with MVP that were assessed
included mitral annular calcification/thickening, papillary
muscle tug or superior traction, and exaggerated posterior
wall motion. Mitral annular calcification was classified in
the parasternal short-axis view as absent, mild (focal),
moderate (calcification of one-third of the mitral annular
ring), or severe (calcification of at least one-half of the mitral
annular ring) (56). The classification of mitral annular
calcification was confirmed qualitatively on the parasternal
long-axis and apical four-chamber views for extent of
calcification and thickening. Papillary muscle superior trac-
tion or tug was defined as exaggerated superior motion of
the papillary muscle toward the mitral annulus during
systole, in parallel with the superior leaflet displacement
(57). The posterior mitral annulus and adjacent left ventric-
ular (LV) wall were examined for exaggerated inward
systolic motion in the parasternal and apical long-axis views.
Statistical methods. Analysis of covariance (58) was used
to test for differences between subjects with and without
MVP on continuous echocardiographic variables. Least
squares means and standard errors are presented. Logistic
regression analysis (59) was used to test for differences
between subjects with and without MVP in the dichoto-
mous echocardiographic variables. Left atrial and LV cham-
ber sizes, LA volume, and mitral annular diameter were
adjusted for age, gender, height, and body mass index. The
following variables were adjusted for age, gender, and body
mass index: mitral leaflet thicknesses and lengths, degree of
MR, LV ejection fraction, mitral annular calcification,
papillary muscle tug, and exaggerated posterior wall motion.
All comparisons were made by pooling subjects with classic
and nonclassic MVP and comparing the pooled sample with
those without MVP. This was an a priori decision made
because of the relatively small sample size of those with
prolapse. A two-sided p value of0.05 was the criterion for
statistical significance. All analyses were conducted using
SAS (60) on a Sun Ultrasparc Workstation (Sun Microsys-
tems, Santa Clara, California).
RESULTS
Diagnosis of MVP. By quantitative evaluation, 46 subjects
had classic MVP and 37 had nonclassic MVP. The remain-
ing subjects did not meet quantitative criteria for MVP,
including all 150 matched subjects whose initial qualitative
evaluation did not suggest MVP (61).
Age and gender. The mean age was 56.7  1.5 years
(gender-adjusted least squares mean  standard error) for
those with classic MVP, 55.4  1.6 years for those with
nonclassic MVP, and 54.7  0.2 years for those without
MVP (p  0.19). The age range for the overall sample was
26 to 84 years. The gender distribution among subjects with
classic and nonclassic MVP versus those without MVP was
similar; 60% of subjects with MVP were female versus 53%
of those without MVP (p  0.21) (61).
Leaflet and annular measures. Echocardiographic features
associated with MVP are reported in Table 1. Anterior
mitral leaflet length was mildly increased in subjects with
nonclassic and classic MVP compared with those without
MVP (Table 1), but mean values did not exceed the range
of 21 to 24 mm reported in the anatomic (62,63) or
echocardiographic (64) literature for normal subjects. Pos-
terior leaflet length was greater in those with MVP, with the
average rising above the reported normal range of 12 to






(n  217) p Value*
Maximal leaflet displacement (mm) 3.8  1.0 3.1  0.6 0.5  2.0 NA
Maximal leaflet thickness (d) (mm) 5.6  0.1 4.3  0.1 3.6  0.1 NA
Anterior leaflet thickness (d) (mm) 5.0  0.1 3.9  0.1 3.3  0.04 NA
Posterior leaflet thickness (d) (mm) 5.6  0.1 4.1  0.1 3.4  0.1 NA
Anterior leaflet length (mm) 23.9  0.4 22.2  0.5 19.3  0.2 0.0001
Posterior leaflet length (mm) 15.0  0.2 14.0  0.3 12.2  0.1 0.0001
Mitral annular diameter (mm) 34.5  0.4 32.0  0.5 29.1  0.2 0.0001
Mitral regurgitation (%) 15.1  1.4 (mild) 8.9  1.5 (trace) 2.4  0.6 (trace) 0.0001
Mitral annular calcification† 11 (20.4) 7 (17.5) 11 (4.5) 0.0001
Papillary muscle tug 15 (33.0) 11 (30.0) 1 (0.4) 0.0001
Posterior wall motion 44 (95.4) 36 (100) 60 (26.5) 0.0001
Maximum leaflet displacement is expressed as an unadjusted mean  standard deviation. All other measurements (least squares
means  standard errors) are adjusted for age, gender, and body mass index, except mitral annular diameter which was also
adjusted for height. *p values compare classic MVP  nonclassic MVP versus no MVP. †Mitral annular calcification was
considered significant if moderate or severe.
d  diastole; MVP  mitral valve prolapse; NA  not applicable because measurements differ by group definition.
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14 mm only for the classic group. In addition, mitral annular
diameter was increased in those with MVP. The subjects
with MVP had a higher prevalence of significant mitral
annular calcification than those without MVP. Papillary
muscle tug or superior traction occurred almost exclusively
in subjects with MVP. Exaggerated posterior LV wall
motion occurred in almost all patients with MVP, but was
also seen in 26.5% of those without MVP.
MR. The extent of MR was significantly higher in subjects
with versus those without MVP, but the average percent jet
area was only 15.1 (mild MR, Table 1) in those with classic
MVP and 8.9 (trace MR) in those with nonclassic MVP. In
the classic group, only 3 of 46 subjects (6.5%) had severe
MR by Doppler color flow mapping. There were no subjects
with severe MR in the nonclassic group, and one, or 0.5%,
in those without MVP. The vast majority of subjects were
only mildly affected: 70% of subjects in the classic group had
no, trace, or mild MR, as did 86% of those with nonclassic
MVP and 98% of those without MVP (Fig. 1).
LA and LV measures. Adjusting for age, gender, height,
and body mass index, LA anteroposterior and mediolateral
diameters, LA volumes, and LVIDd were significantly but
mildly higher in subjects with MVP compared with subjects
without MVP (Table 2). However, the vast majority of
subjects with MVP had dimensions within the range of
normal with few rising above them (65,66) (Table 3).
Indexing chamber dimensions for height did not cause
substantive differences in the results. Left atrial size corre-
lated with MR in the mediolateral (r  0.22) and antero-
posterior (r  0.26) dimensions; LA anteroposterior diam-
eter was increased in 4 of 24, or 17%, subjects with
moderate to severe MR versus 5 of 276, or 1.8%, of those
Figure 1. The distribution of mitral regurgitation severity among the subjects in the study. MVP  mitral valve prolapse.






(n  217) p Value*
LA diameter (ap) (cm) 3.29  0.04 3.09  0.05 3.00  0.02 0.0001
LA diameter (ml) (cm) 3.98  0.07 3.77  0.07 3.61  0.03 0.0001
LA diameter (is) (cm) 4.83  0.08 4.57  0.09 4.70  0.04 0.99
LA volume (cm3) 33.6  1.0 28.3  1.1 27.0  0.5 0.0001
LVIDd (cm) 4.63  0.04 4.40  0.05 4.40  0.02 0.0038
LVIDs (cm) 2.92  0.04 2.78  0.05 2.78  0.02 0.03
LV ejection fraction (%) 70.0  0.9 69.4  1.0 69.8  0.4 0.84
All measurements (least squares means  standard errors) are adjusted for age, gender, height, and body mass index, except
ejection fraction which was not adjusted for height. *p values compare classic MVP  nonclassic MVP versus no MVP.
ap anteroposterior; is inferosuperior; LA left atrial; LV left ventricular; LVIDd left ventricular internal diameter
in end-diastole; LVIDs  left ventricular internal diameter in end-systole; ml  mediolateral; MVP  mitral valve prolapse.
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with none, trace, or mild MR. Ejection fraction was not
different among the groups.
DISCUSSION
Mitral valve prolapse can be clearly identified by echocar-
diography in a community-based sample, with superior
leaflet displacement and increases in leaflet thickness, leaflet
length, and MR. Nevertheless, these echocardiographic
features and associations, although significant, are relatively
mild. Severe MR is uncommon, and the vast majority, even
of those with thickened leaflets, have no, trace, or mild MR.
Left atrial size is similarly only mildly increased in these
subjects with MVP, with average values that lie within the
normal range; atrial size lies above this range in only a small
proportion of those with classic MVP and thickened leaf-
lets. Leaflet length lies within or only slightly above the
normal range described in anatomic and echocardiographic
series in the classic group (62–64) and is within the normal
range in the nonclassic group. Anterior leaflet length lies
well below the 29 mm associated with congestive heart
failure and the 26 mm associated with sudden death in a
recent autopsy series (15). Left ventricular dysfunction is
absent, and mild LV dilation rarely present. Therefore, the
MVP is a definable entity, but with relatively benign
echocardiographic manifestations in a general outpatient
population.
Comparison with previous literature. Previous studies of
MVP have often focused on echocardiographic abnormali-
ties and their association with clinical complications (3–19).
Tresch et al. (6), for example, found dilated LA and LV in
90% of patients with MVP requiring mitral valve repair. In
a large series of subjects with MVP, Zuppiroli et al. (16)
found a high likelihood of complications, including cardiac
death, and mitral valve replacement from progressive MR,
in patients with enlarged LA and LV. Studies emphasizing
complications, however, have generally used hospital-based
or referral samples, increasing the likelihood of finding
echocardiographic and clinical abnormalities (16).
A different picture emerges from this study of an uns-
elected outpatient sample. The subjects with MVP in this
population did, in fact, have echocardiographic abnormali-
ties, consistent with prior studies (4,5,9,14,15,40,67). These
findings, however, were typically mild, uncommonly ex-
ceeding the normal range or increasing to the levels seen in
patients with complications. (Only one patient in this
cohort has needed mitral valve repair for important MR
with atrial fibrillation.) Therefore, even when MVP is
diagnosed with the more specific criteria currently used—
which would be expected to enrich for patients with definite
abnormalities—there is a relatively benign constellation of
associated findings. As in the case with hypertrophic car-
diomyopathy, this reflects study design: studies at referral
institutions suggest a frequently symptomatic disease with a
high rate of complications, whereas eliminating such patient
referral and selection biases in outpatient samples can
dramatically change the perception of disease (20,21).
Features associated with MVP. Mitral annular calcifica-
tion occurred more frequently in Framingham subjects with
MVP. It has been associated with both MR and MVP
(68–70) and ascribed to increased mitral leaflet stress related
to abnormal motion. It should be noted that echogenic
appearances are nonspecific for calcification (71), however,
and may represent annular thickening related to the myxo-
matous process. Papillary muscle superior tug occurred
almost exclusively in subjects with important leaflet dis-
placement, as in the prior literature (57). Clinically, it has
yet to be demonstrated that such traction increases the
propensity for lethal arrhythmias, as it does experimentally
(72). Exaggerated inward posterior wall motion has been
previously reported (70) but is not well understood; one
potential mechanism would be traction by mural or other
chordae on the adjacent myocardium. These findings, espe-
cially the abnormal papillary muscle and myocardial motion,
are currently of greatest value as visual cues to heighten the
awareness of the echocardiographer to the possibility of
MVP.
Study limitations. Although the overall study sample was
large, the total number of subjects with MVP was modest.
Nevertheless, the purpose of the study was achieved,
namely, to examine the echocardiographic features and
associations of MVP in an unselected outpatient sample.
Unlike studies of patients seeking medical attention for
complications of MVP or concerns regarding it, this study
seeks to characterize MVP in the community, which has not
been well described; this difference in population can
explain differences in the apparent severity of presentation.
In addition, the sample was predominantly Caucasian and it
is possible that the results may not be generalized to other
ethnic and racial groups. This study was cross-sectional, and
additional studies are exploring progression. Of note is the
fact that the single individual with MVP who required
surgical repair before the study was excluded from the
analysis for LA and LV size because they were not available
in a comparable unoperated state at the same time that other
subjects were studied. This may slightly skew these dimen-
sions. Finally, we used the jet/LA area ratio as the best
available quantitative measure at the time the echoes were
obtained (53). This single-frame measure may, for example,
overestimate MR that is limited to late systole, compared
with more recent quantitative and integrated assessments













Increased LA diameter (ap) (cm) 3 (6.5) 0 (0) 6 (2.8)
Increased LA diameter (ml) (cm) 5 (11) 1 (2.7) 1 (0.5)
Increased LA volume (cm3) 4 (8.7) 1 (2.7) 3 (1.4)
Increased LVIDd (cm) 3 (6.5) 0 (0) 0 (0)
Reference values: LA diameter (ap)  3.8 cm; LA diameter (ml)  4.7 cm; LA
volume  46 cm3; LVIDd  5.3 cm.
Abbreviations as in Table 2.
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(73). However, comparison with the routine semiquantita-
tive grading done independent of this MVP study, which
integrates multiple aspects of jet size over time in several
views, showed no major over- or underestimation.
Summary and clinical implications. We combined an
unselected study sample and current 2-D echocardiographic
criteria for the diagnosis of MVP to explore the echocar-
diographic features of MVP in the community. We found
that although the subjects with MVP in the Framingham
Heart Study are significantly different from those without
MVP in the defining and classifying features of leaflet
displacement and thickness, they display a far more benign
profile of associated valvular, atrial, and ventricular abnor-
malities than previously reported in hospital- or referral-
based series. This profile of echocardiographic abnormalities
such as MR and LA enlargement, which is associated with
clinical complications, establishes the perception of disease
severity, and a low frequency may allay anxiety for the
individual diagnosed with MVP in the general outpatient
setting. The frequent presence of no or trace MR in subjects
with MVP is also relevant in considerations regarding
antibiotic prophylaxis and in balancing its potential risks
and benefits (74,75). As in studies of hypertrophic cardio-
myopathy, the common theme is emerging that the profile
of disease in patients with severe symptoms and demon-
strated complications is not applicable to most individuals
diagnosed by screening or routine evaluation in the general
population, whose findings are far more benign.
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